• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home ENT

Doxepin rinse reduces pain of oral mucositis during radiotherapy

byMonica ParksandAndrew Bishara
April 18, 2014
in ENT, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Oral doxepin rinse significantly reduces the incidence of painful oral mucositis (OM) during radiotherapy for head and neck cancers.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Painful oral mucositis is commonly associated with radiotherapy for head and neck cancers, and frequently requires treatment with systemic analgesics. The purpose of this study was to evaluate the use of doxepin hydrochloride, a tricyclic antidepressant with anesthetic properties, in the management of the pain associated with this condition. The primary endpoint measured was pain reduction measured by the area under the curve (AUC) on the pain scale. At the conclusion of this study, the authors found that AUC was significantly reduced in the doxepin arm compared to placebo. The limitation of this study is that doxepin was not compared to magic mouthwash rinses, the current most commonly prescribed therapy for mucositis, and further investigation is warranted.

Click to read the study in JCO

In-Depth [randomized controlled trial]: In this randomized, controlled trial, 155 patients were enrolled who were undergoing radiotherapy with or without chemotherapy for histologically proven head and neck malignancy. Patients were randomized to either a doxepin oral rinse or to placebo, then crossed over to receive the alternate treatment on the following day. Pain questionnaires were given at the time of treatment, then at 5, 15, 30, 60, 120 and 240 minutes. Patients were also given the option to continue the doxepin treatment. This was a double-blinded study. The primary endpoint measured was pain reduction measured by the area under the curve (AUC) on the pain scale. At the conclusion of this study, the authors found that AUC was significantly reduced in the doxepin arm compared to placebo (-9.1 versus -4.7, P < 0.001).

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

RELATED REPORTS

Accelerated approval drugs incur significant fee-for-service Medicare costs

Unsweetened coffee consumption is associated with reduced risk of mortality

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: oncologyoral mucositisoral ulcerpainradiotherapy
Previous Post

Quadrivalent HPV vaccine in young women [Classics Series]

Next Post

Interpartum HIV viral load suppression improves outcomes

RelatedReports

Estrogen withdrawal associated with perimenopausal depression
Oncology

Accelerated approval drugs incur significant fee-for-service Medicare costs

June 22, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

Medical cannabis provides little improvement to sleep in chronic pain patients

May 27, 2022
Next Post
HIV-infected infant potentially cured with antiretroviral therapy

Interpartum HIV viral load suppression improves outcomes

Oral glucose tolerance test preferred for pre-diabetes screening in PCOS

Receptor responsible for fertilization discovered

Oral contraceptive pills associated with reduction in ovarian cancer incidence

Free drug samples may alter prescription habits of dermatologists

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.